Sodium Butyrate Side Effects: What Studies Report

What This Page Covers

Sodium butyrate is the sodium salt of butyric acid, a short-chain fatty acid that gut bacteria produce when they ferment dietary fibre. It is not a peptide, but it appears frequently alongside peptide and metabolic-health topics because much of the same literature deals with gut barrier function, inflammation signalling and microbiome composition. This page summarises what published studies have actually recorded about tolerability, route-related problems and safety limitations. It does not tell anyone what to do with the compound, and it is deliberately narrow: mechanism, biology and study design are taught elsewhere on PeptideU, while this page stays on the question of what the literature reports regarding safety.

This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision. Nothing below should be read as a protocol, a recommendation or an endorsement of any product.

How Safety Information Appears in the Sodium Butyrate Literature

An important structural point about this field: most sodium butyrate papers are efficacy or mechanism papers. Researchers typically test whether butyrate changes an inflammatory marker, a microbiome profile or a disease score, and adverse events appear as secondary reporting rather than as the primary question. Animal studies in the verified literature — mice, and broiler chickens — were designed around disease models, not around dose-limiting toxicity. That means the absence of reported harm in a given paper reflects what that paper was built to measure, which is not the same as a demonstration of safety.

A second point is that "sodium butyrate" in the literature is not one product. The verified papers include plain sodium butyrate given to animals, microencapsulated sodium butyrate given to patients, polymeric butyrate donors, bacterial outer membrane vesicles delivered by microneedle, and tributyrin, a triglyceride prodrug of butyrate. Tolerability observations attach to a specific formulation and route, and do not transfer automatically between them.

Human Studies and Tolerability: What Studies Report

Oral sodium butyrate in pediatric obesity

The most substantial human dataset in the verified list comes from a randomized clinical trial in children with obesity, in which researchers administered oral sodium butyrate at 20 mg/kg/day for six months and assessed body mass index and metabolic outcomes against placebo (PMID 36469320). Because that trial ran for half a year in a paediatric population, it is the closest thing this body of work has to a medium-term tolerability record for an oral butyrate salt, and the study report described the supplementation as tolerated over the treatment period (PMID 36469320). The trial was not designed as a toxicology study, and its findings apply to the specific oral preparation, dose and age group studied.

Microencapsulated sodium butyrate during pelvic radiotherapy

A single-centre prospective study examined microencapsulated sodium butyrate in the prevention of acute radiotherapy proctitis in patients receiving pelvic irradiation, with researchers tracking proctitis symptoms as the outcome of interest (PMID 40649157). This is a useful example of why gastrointestinal context matters when reading reported side effects: in a population already experiencing radiation-related bowel symptoms, distinguishing a supplement effect from the underlying condition is methodologically difficult, and the study design — single centre, prospective, without a randomized comparator described in its title — limits how far its tolerability observations can be generalised (PMID 40649157).

An irritable bowel syndrome trial protocol

A randomized, double-blind, placebo-controlled trial of microencapsulated sodium butyrate combined with probiotics and short-chain fructooligosaccharides in patients with irritable bowel syndrome has been published as a study protocol, meaning researchers described the planned design and endpoints rather than results (PMID 36362815). Protocol papers are frequently mistaken for outcome papers in secondary summaries. No tolerability conclusions can be drawn from a protocol, and the combination design in that protocol would also make it difficult to attribute any future event to butyrate alone (PMID 36362815).

Tributyrin, a butyrate prodrug, in Parkinson's disease

An open-label target engagement study examined dietary tributyrin supplementation in people with Parkinson's disease, with researchers testing whether the prodrug engaged its intended biological target rather than testing clinical benefit (PMID 41271518). Open-label designs have no placebo arm, so reported symptoms during the study cannot be separated from expectation effects or from the natural course of the disease. Target engagement studies are early-phase work, and the paper's value lies in feasibility and biomarker signal rather than in any safety determination (PMID 41271518).

Palatability, Odour and Delivery Problems: What Studies Report

One of the clearest "side effect" themes in this literature is not a physiological adverse event at all — it is the practical difficulty of administering butyrate. Researchers developing polyvinyl butyrate nanoparticles as butyrate donors for colitis treatment framed their work around the limitations of giving butyrate directly, designing a polymer that releases butyrate rather than delivering the free acid or salt (PMID 35014354). The same logic explains why the human studies above used microencapsulated sodium butyrate rather than plain salt (PMID 40649157), and why other groups have pursued entirely different routes.

Delivery engineering appears again in oncology models: one group loaded oxaliplatin and sodium butyrate into bacterial outer membrane vesicles and delivered them with dissolving microneedles in a rectal cancer model, an approach researchers adopted to concentrate the payload locally (PMID 40847351). Readers comparing side-effect reports across papers should note that a locally delivered vesicle formulation and an oral capsule are different exposures, and neither predicts the tolerability of the other.

Animal Studies: Models, Routes and Reported Observations

The animal literature is broad in disease scope and narrow in safety reporting. In one study, researchers gave sodium butyrate to ApoE-deficient mice and reported changes in the ocular surface microbiome alongside attenuated inflammation in a meibomian gland dysfunction model (PMID 41402861). In a fibrosis model, sodium butyrate attenuated the peritoneal fibroproliferative process in mice (PMID 36459573), and in a separate model researchers reported that sodium butyrate downregulated implant-induced inflammation in mice (PMID 32125592).

Metabolic and musculoskeletal models add further examples. Sodium butyrate ameliorated type 2 diabetes-related sarcopenia in mice through an IL-33-independent ILC2s/IL-13/STAT3 signalling pathway, according to the study authors (PMID 36733489). In poultry, researchers reported that sodium butyrate ameliorated thiram-induced tibial dyschondroplasia and gut microbial dysbiosis in broiler chickens (PMID 36183428/). A related line of work approached butyrate from the opposite direction: polydisperse polystyrene microplastics exacerbated colitis in mice through disruption of a gut microbiota–butyrate–PPARγ axis, implicating loss of endogenous butyrate rather than administration of a supplement (PMID 41864031).

What the Verified Literature Does Not Establish

Reading this set of papers together, several safety questions remain open rather than answered:

• Long-term human exposure. The longest human exposure described in the verified set is the six-month oral course studied in children with obesity (PMID 36469320). Nothing here speaks to multi-year use.
• Sodium content. None of the verified papers reported outcomes related to the sodium load of the salt form, so this remains uncharacterised in this literature.
• Drug interactions. The oncology work combined sodium butyrate with oxaliplatin in a delivery system rather than testing interaction safety in patients (PMID 40847351), and the IBS protocol combines butyrate with probiotics and prebiotics without published results (PMID 36362815).
• Route-specific effects. Nanoparticle donors (PMID 35014354) and microneedle-delivered vesicles (PMID 40847351) were preclinical delivery experiments, not human safety studies.
• Species translation. Findings in mice and broiler chickens, including the poultry bone model (PMID 36183428), do not establish human dose-response or human adverse-event profiles.

How To Read Side-Effect Claims In This Area

1. Check whether the paper is a protocol or a result. A published design contains no outcome data (PMID 36362815).
2. Check the formulation. Microencapsulated capsules, polymer donors and prodrugs behave differently from the free salt, which is the explicit rationale for donor chemistry (PMID 35014354).
3. Check for a control arm. Open-label target engagement work cannot separate reported symptoms from expectation or disease progression (PMID 41271518).
4. Check the population. A paediatric obesity cohort (PMID 36469320) and a pelvic radiotherapy cohort (PMID 40649157) have very different baseline symptom rates.

In short, the verified literature describes a compound studied mainly for gut, metabolic and inflammatory endpoints, with tolerability reported as a secondary observation and with formulation and palatability problems driving much of the delivery research. Decisions about any supplement or investigational compound belong with a licensed clinician who can review an individual's full medical context.

References

• Therapeutic Effects of Butyrate on Pediatric Obesity: A Randomized Clinical Trial (JAMA Network Open, 2022)
• Microencapsulated Sodium Butyrate in the Prevention of Acute Radiotherapy Proctitis: Single-Center Prospective Study (Journal of Clinical Medicine, 2025)
• Effects of Microencapsulated Sodium Butyrate, Probiotics and Short Chain Fructooligosaccharides in Patients with Irritable Bowel Syndrome: A Study Protocol of a Randomized Double-Blind Placebo-Controlled Trial (Journal of Clinical Medicine, 2022)
• Dietary tributyrin supplementation in Parkinson's disease: An open-label target engagement study (Neurotherapeutics, 2026)
• Polyvinyl Butyrate Nanoparticles as Butyrate Donors for Colitis Treatment (ACS Applied Bio Materials, 2021)
• Dissolving microneedles enabled delivery of Oxaliplatin-sodium butyrate loaded outer membrane vesicles against rectal cancer (Journal of Translational Medicine, 2025)
• Sodium butyrate modulates ocular surface microbiome and attenuates inflammation of meibomian gland dysfunction in ApoE(-/-) mice (Microbiome, 2025)
• Sodium butyrate attenuates peritoneal fibroproliferative process in mice (Experimental Physiology, 2023)
• Sodium Butyrate Downregulates Implant-Induced Inflammation in Mice (Inflammation, 2020)
• Sodium Butyrate Ameliorates Type 2 Diabetes-Related Sarcopenia Through IL-33-Independent ILC2s/IL-13/STAT3 Signaling Pathway (Journal of Inflammation Research, 2023)
• Sodium butyrate ameliorates thiram-induced tibial dyschondroplasia and gut microbial dysbiosis in broiler chickens (Ecotoxicology and Environmental Safety, 2022)
• Polydisperse polystyrene microplastics exacerbate colitis through gut microbiota-butyrate-PPARγ axis disruption in mice (Journal of Hazardous Materials, 2026)